Research Reports Gold Mining | Guotou Securities: Xiamen Amoytop Biotech's performance is impressive, maintaining a "Buy-A" rating.

Gelonghui FinanceJan 17 17:02

Tebao Biotech (688278): Outstanding performance, new indications for long-acting interferon, and approval of long-term growth hormone are worth looking forward to

State Investment SecuritiesJan 16 14:27

Tebao Biotech (688278): Slow hepatitis B treatment continues to deepen, and the company's performance continues to grow at a high level

SinolinkJan 15 00:00

Tebao Biotech (688278): Prospects for clinical cure of hepatitis B are broad, Pegbin's first-mover advantage continues to be released

Western SecuritiesDec 30, 2024 07:27

Tebao Biotech (688278): Optimistic about performance acceleration opportunities brought about by changes in supply and demand next year

HAITONG SECDec 20, 2024 15:57

Tebao Biotech (688278): Optimistic about performance acceleration opportunities brought about by changes in supply and demand next year

HAITONG INT'LDec 20, 2024 00:00

Tebao Biotech (688278): Maintaining high profit growth in 24Q3 and increasing depth in the hepatitis B sector

huaan securitiesOct 27, 2024 00:00

Tebao Biotech (688278): Slow hepatitis B cure accelerates and deepens, and the company's performance continues to exceed expectations

sinolinkOct 25, 2024 10:31

Tebao Biotech (688278): Pegbin continues to rapidly increase profit margins

china merchantsOct 25, 2024 00:00

Tebao Biotech (688278): Third-quarter results exceeded expectations and accelerated release after Pegbin collection

Galaxy SecuritiesOct 24, 2024 00:00

Tebao Biotech (688278): Hepatitis B clinical cure market space is broad, and continuous doses of Pegobin can be expected

Donghai SecuritiesOct 16, 2024 07:16

Tebao Biotech (688278): Interim report on steady growth, equity incentives highlight management confidence

Sep 3, 2024 13:16

Tebao Biotech (688278): Rapid growth in revenue and net profit, equity incentive plans demonstrate confidence in development

Aug 23, 2024 16:16

Tebao Biotech (688278): Equity incentives indicate confidence in performance growth long-term interferon+long-term whitening drug+long-term growth hormone are expected to guarantee the sustainability of growth

Aug 23, 2024 07:41

Tebao Biotech (688278): 24H1 management tends to be a steady pioneer in the field of hepatitis B treatment

Aug 22, 2024 00:00

Tebao Biotech (688278): Pegbin maintains rapid growth and the new product Pekin contributes more

Aug 21, 2024 00:00

Tebao Biotech (688278): Performance continues to grow strongly, equity incentives highlight confidence in long-term development

Aug 21, 2024 00:00

Tebao Biotech (688278): Long-acting interferon leading slow hepatitis B has outstanding clinical cure potential

Aug 20, 2024 19:06

Tebao Biotech (688278): Joint development of new hepatitis B drugs with ALIGOS to explore new models of cooperation

Jul 25, 2024 11:26

Tebao Biotech (688278): Leading provider of hepatitis B interferon treatment, deepens development of recombinant protein drugs

Jun 26, 2024 00:00